133 related articles for article (PubMed ID: 29374428)
1. [Metalloproteases and their inhibitors: role in pathogenesis of selected examples].
Siemińska-Kuczer A; Vertyporokh L; Andrejko M; Wojda I; Stączek S; Zdybicka-Barabas A; Grygorczuk K; Cytryńska M
Postepy Biochem; 2017; 63(4):269-276. PubMed ID: 29374428
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of the insect metalloproteinase inhibitor against infections caused by Pseudomonas aeruginosa.
Eisenhardt M; Schlupp P; Höfer F; Schmidts T; Hoffmann D; Czermak P; Pöppel AK; Vilcinskas A; Runkel F
J Pharm Pharmacol; 2019 Mar; 71(3):316-328. PubMed ID: 30408181
[TBL] [Abstract][Full Text] [Related]
3. Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor.
Kany AM; Sikandar A; Yahiaoui S; Haupenthal J; Walter I; Empting M; Köhnke J; Hartmann RW
ACS Chem Biol; 2018 Sep; 13(9):2449-2455. PubMed ID: 30088919
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the binding specificity of two bacterial metalloproteases, LasB of Pseudomonas aeruginosa and ZapA of Proteus mirabilis, using N-alpha mercaptoamide template-based inhibitor analogues.
Carson L; Cathcart GR; Ceri H; Walker B; Gilmore BF
Biochem Biophys Res Commun; 2012 Jun; 422(2):316-20. PubMed ID: 22575503
[TBL] [Abstract][Full Text] [Related]
5.
Konstantinović J; Yahiaoui S; Alhayek A; Haupenthal J; Schönauer E; Andreas A; Kany AM; Müller R; Koehnke J; Berger FK; Bischoff M; Hartmann RW; Brandstetter H; Hirsch AKH
J Med Chem; 2020 Aug; 63(15):8359-8368. PubMed ID: 32470298
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.
Gellatly SL; Hancock RE
Pathog Dis; 2013 Apr; 67(3):159-73. PubMed ID: 23620179
[TBL] [Abstract][Full Text] [Related]
7. The contribution of Pseudomonas aeruginosa virulence factors and host factors in the establishment of urinary tract infections.
Newman JW; Floyd RV; Fothergill JL
FEMS Microbiol Lett; 2017 Aug; 364(15):. PubMed ID: 28605563
[TBL] [Abstract][Full Text] [Related]
8. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Activity of Berberine with Azithromycin against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung In Vitro and In Vivo.
Li Y; Huang J; Li L; Liu L
Cell Physiol Biochem; 2017; 42(4):1657-1669. PubMed ID: 28738346
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous production of proteases from Brazilian clinical isolates of Pseudomonas aeruginosa.
Galdino ACM; Viganor L; Ziccardi M; Nunes APF; Dos Santos KRN; Branquinha MH; Santos ALS
Enferm Infecc Microbiol Clin; 2017 Dec; 35(10):630-637. PubMed ID: 27480954
[TBL] [Abstract][Full Text] [Related]
11. The clinical challenge of infections due to Pseudomonas aeruginosa.
Young LS
Rev Infect Dis; 1984; 6 Suppl 3():S603-7. PubMed ID: 6443761
[TBL] [Abstract][Full Text] [Related]
12. The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo.
Uusitalo P; Hägglund U; Rhöös E; Scherman Norberg H; Elofsson M; Sundin C
J Antibiot (Tokyo); 2017 Aug; 70(9):937-943. PubMed ID: 28588224
[TBL] [Abstract][Full Text] [Related]
13. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.
Jakobsen TH; Bjarnsholt T; Jensen PØ; Givskov M; Høiby N
Future Microbiol; 2013 Jul; 8(7):901-21. PubMed ID: 23841636
[TBL] [Abstract][Full Text] [Related]
14. Potential Use of Dimethyl Sulfoxide in Treatment of Infections Caused by Pseudomonas aeruginosa.
Guo Q; Wu Q; Bai D; Liu Y; Chen L; Jin S; Wu Y; Duan K
Antimicrob Agents Chemother; 2016 Dec; 60(12):7159-7169. PubMed ID: 27645245
[TBL] [Abstract][Full Text] [Related]
15. Metalloproteases from Pseudomonas aeruginosa degrade human RANTES, MCP-1, and ENA-78.
Leidal KG; Munson KL; Johnson MC; Denning GM
J Interferon Cytokine Res; 2003 Jun; 23(6):307-18. PubMed ID: 12859857
[TBL] [Abstract][Full Text] [Related]
16. Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections.
Wagner S; Sommer R; Hinsberger S; Lu C; Hartmann RW; Empting M; Titz A
J Med Chem; 2016 Jul; 59(13):5929-69. PubMed ID: 26804741
[TBL] [Abstract][Full Text] [Related]
17. Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.
Berube BJ; Murphy KR; Torhan MC; Bowlin NO; Williams JD; Bowlin TL; Moir DT; Hauser AR
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807906
[No Abstract] [Full Text] [Related]
18. Identification of an immunomodulating metalloprotease of Pseudomonas aeruginosa (IMPa).
Bardoel BW; Hartsink D; Vughs MM; de Haas CJ; van Strijp JA; van Kessel KP
Cell Microbiol; 2012 Jun; 14(6):902-13. PubMed ID: 22309196
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.
Tolker-Nielsen T
APMIS Suppl; 2014 Dec; (138):1-51. PubMed ID: 25399808
[TBL] [Abstract][Full Text] [Related]
20. Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model.
Luo J; Dong B; Wang K; Cai S; Liu T; Cheng X; Lei D; Chen Y; Li Y; Kong J; Chen Y
PLoS One; 2017; 12(4):e0176883. PubMed ID: 28453568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
